Amir Weisberg – Chief Executive Officer

Mr. Weisberg has been leading PolyPid since 2010 and has 20 years of experience as an entrepreneur and CEO of start-up companies with two financial exits. Prior to PolyPid, Mr. Weisberg managed start-up companies in the Life Science sphere, from incubator stage to clinical trials, including leading the financing rounds for these companies.

Noam Emanuel, Ph.D. – Chief Scientific Officer

Dr. Emanuel has vast experience in biotechnology projects, including development of drug delivery systems and immunology. His extensive expertise includes immunotherapy, vaccines, immunodiagnostics, systemic and local drug-delivery, and medical devices. Dr. Emanuel has a number of approved patents in the field of drug delivery and diagnostics. Dr. Emanuel is a co-founder of PolyPid and served as its CEO during the company’s first three years. He received his Ph.D. degree from the Faculty of Medicine at the Hebrew University of Jerusalem.

Dikla Czaczkes Akselbrad – Executive Vice President and Chief Financial Officer

Ms. Czaczkes Akselbrad spent over 12 years with Compugen the last 7 years of which as Chief Financial Officer where she played a leading role in numerous capital transactions raising over $130M. Before joining Compugen, Ms. Czaczkes Akselbrad was Chief Financial Officer of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She holds an MBA in finance and a BA in accounting and economics, both from Tel Aviv University, and is a certified public accountant in Israel.

Shaul Mukhtar, Ph.D. – Chief Operating Officer

Dr. Shaul Mukhtar has vast experience with a demonstrated history of working in the pharmaceuticals and medical devices industry. Skilled in Research and Development (R&D), business and operational management, with extensive know how in diversified key areas. Shaul spent 15 years at Teva Pharmaceuticals, the last 5 years of which Chief Operating Officer and Regional R&D manager of Teva Japan & S. Korea, where he was responsible for all the back end processes in the relevant markets, such as portfolio management, operations, R&D, QA, RA, Supply chain, sourcing and commercial readiness.

Before Joining Teva Pharmaceuticals he served as the Chief Pharmacist of the Israeli Defense Forces and VP medical technologies in Sheba Medical Center. Dr. Mukhtar holds Ph.D. degree in Pharmaceutical Sciences from the Hebrew University, Jerusalem, and MBA in International Business Administration from Tel Aviv University.

Dalit Hazan – VP R&D and Regulatory Affairs

Ms. Hazan has over 20 years of diversified managerial experience in the Regulatory Affairs field. Ms. Hazan has vast experience in registration submissions of different pharmaceutical dosage forms and in different markets such as US, EU, CA, IL and rest of the world. Previously she held Regulatory Affairs managerial positions at Teva Pharmaceuticals Ltd. (Head of RA Department) as well as harmonization of RA procedures globally (as part of Global RA compliance), and Dexcel Pharma Ltd. (RA Manager). Ms. Hazan holds  an M.Sc. degree in Physiology and Pharmacology from Sackler Faculty of Medicine, Tel Aviv University.

Ori Warshavsky – VP Marketing

Ori has over 15 years of international experience in the pharmaceuticals industry with experience ranging from corporate strategy and business development to marketing and market access. Prior to joining Polypid Ori spent 10 years at Teva Pharmaceuticals with his last role being Senior Director of Oncology Marketing where he led the launch of several oncology products. Earlier in his career Ori served as the Head of Market Access for Teva in Canada and as Chief of Staff to the CEO of Teva’s global generics business. Ori started his career as a biotech engineer both in Israel and the US.

Ori holds a B.Sc. degree in Biotechnology Engineering from the Ben-Gurion University and an MBA from Duke University’s Fuqua School of Business.

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >